ArticleThe oncologist2025

Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer.

Ying Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.